Novel CSF biomarkers to discriminate FTLD and its pathological subtypes

• Type of Material: Article
• Authors: Marta del Campo, VU University Medical Center; Daniela Galimberti, University of Milan; Naura Elias, VU University Medical Center; Lynn Boonkamp, VU University Medical Center; Yolande A. Plijnenburg, VU University Medical Center; John C. van Swieten, VU University Medical Center; Kelly Watts, Emory University; Silvia Paciotti, University of Perugia; Tommaso Beccari, University of Perugia; William Hu, Emory University; Charlotte E. Teunissen, VU University Medical Center
• Language: English
• Date: 2018-09-07
• Publisher: Wiley Open Access
• Publication Version: Final Published Version
• Copyright Statement: Copyright © 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. CC BY NC ND 4.0
• Final Published Version (URL): http://dx.doi.org/10.1002/acn3.629
• Title of Journal or Parent Work: Annals of Clinical and Translational Neurology
• Volume: 5
• Issue: 10
• Start Page: 1163
• End Page: 1175
• Grant/Funding Information: This work was funded by Association for Frontotemporal Degeneration grant ; Alzheimer's Drug Discovery Foundation grant ; ZonMw grant .
• Research Categories: Biology, Neuroscience; Health Sciences, Medicine and Surgery; Health Sciences, Pathology

Abstract

Objective: Frontotemporal lobar degeneration (FTLD) is the second most prevalent dementia in young patients and is characterized by the presence of two main protein aggregates in the brain, tau (FTLD‐Tau) or TDP43 (FTLD‐TDP), which likely require distinct pharmacological therapy. However, specific diagnosis of FTLD and its subtypes remains challenging due to largely overlapping clinical phenotypes. Here, we aimed to assess the clinical performance of novel cerebrospinal fluid (CSF) biomarkers for discrimination of FTLD and its pathological subtypes. Methods: YKL40, FABP4, MFG‐E8, and the activities of catalase and specific lysosomal enzymes were analyzed in patients with FTLD‐TDP (n = 30), FTLD‐Tau (n = 20), AD (n = 30), DLB (n = 29), and nondemented controls (n = 29) obtained from two different centers. Models were validated in an independent CSF cohort (n = 188). Results: YKL40 and catalase activity were increased in FTLD‐TDP cases compared to controls. YKL40 levels were also higher in FTLD‐TDP compared to FTLD‐Tau. We identified biomarker models able to discriminate FTLD from nondemented controls (MFG‐E8, tTau, and Aβ 42; 78% sensitivity and 83% specificity) and non‐FTLD dementia (YKL40, pTau, p/tTau ratio, and age; 90% sensitivity, 78% specificity), which were validated in an independent cohort. In addition, we identified a biomarker model differentiating FTLD‐TDP from FTLD‐Tau (YKL40, MFGE‐8, βHexA together with βHexA/tHex and p/tTau ratios and age) with 80% sensitivity and 82% specificity. Interpretation: This study identifies CSF protein signatures distinguishing FTLD and the two main pathological subtypes with optimal accuracy (specificity/sensitivity > 80%). Validation of these models may allow appropriate selection of cases for clinical trials targeting the accumulation of Tau or TDP43, thereby increasing their efficiency and facilitating the development of successful therapies.